2021 Week 35: Bristol-Myers Squibb (NYSE: BMY)

BMY

Portfolio Update

The FiveTwenty portfolio received no dividends in the past week.

Past Week Dividend$0
Current Quarter Dividend$0
LifeTime Dividend$0
Estimated Annual Dividend$0
Dividend Scorecard

The capital allocation for the week of 08/29/2021 to 09/04/2021 will be used to add to our position in Bristol-Myers Squibb (NYSE: BMY)

BMY – Position Update

Since our last check-in on BMY in week 29 of 2021, the company reported Q2 2021 earnings on 07/28/2021. Additionally, the share price decreased 1% from $67.30 to $66.60 during the same period.

Continue reading “2021 Week 35: Bristol-Myers Squibb (NYSE: BMY)”

2021 Week 29: Bristol-Myers Squibb (NYSE: BMY)

BMY

Portfolio Update

The FiveTwenty portfolio received no dividends in the past week.

Past Week Dividend$0
Current Quarter Dividend (Q3 2021)$36.00
LifeTime Dividend$541.34
Estimated Annual Dividend$2,152.01
Dividend Scorecard

The capital allocation for the week of 07/18/2021 to 07/24/2021 will be used to establish a position in Bristol-Myers Squibb (NYSE: BMY).

BMY – Company Profile

Bristol-Myers Squibb (BMY) is an American multinational biopharmaceutical company. The company offer products in hematology, oncology, cardiovascular, and immunology therapeutic classes. It products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, and Yervoy. Official Site | Wikipedia

Continue reading “2021 Week 29: Bristol-Myers Squibb (NYSE: BMY)”